Nonsense mutation at glutamic acid 384, within the segment 2 of the EGFR and c-Abl binding motif of ERRFI1 [22,33], exists in sporadic intrahepatic cholangiocarcinoma and is associated with enhanced cancer regression upon EGFR inhibition [154]. Here, EGFR is linked to intrahepatic cholangiocarcinoma.